Growth hormone releasing hormone receptor agonist MR409 attenuates vascular calcification in diabetic Db/Db mice
CSTR:
Author:
Affiliation:

Department of Physiology, Shenyang Medical University, Shenyang, Liaoning 110034, China)

Clc Number:

R363;R54

  • Article
  • | |
  • Metrics
  • |
  • Reference [31]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    Aim To study the protective effect of growth hormone releasing hormone receptor agonist MR409 on vascular calcification (VC) in gene deficient mice Db/Db diabetic mice (Db/Db mice). Methods With 12-week-old male wild-type (WT) C57BL/6 mice as the WT group (control group), 12-week-old male Db/Db mice were randomly divided into Db/Db group (diabetes group) and MR409 group (MR409 treatment group). MR409 group was given MR409 (15 μg/time) every other day for 8 weeks. At the end of the 8th week, the mouse serum alkaline phosphatase (ALP) and blood glucose levels were tested. HE staining was used to observe the morphological changes of aorta in mice. Calcium salt deposition in aorta was detected by von Kossa staining and alizarin red staining. Endothelium-dependent vasodilation function was measured by in vitro vascular perfusion system. Aortic calcification-related protein Runt-related transcription factor 2 (Runx2) protein expression was detected by immunohistochemical staining. Aortic reactive oxygen species (ROS) level was detected by dihydroethidium fluorescent staining. Results Compared with WT group, serum ALP activity increased, blood vessel wall thickness increased, vasodilation function decreased, and aortic ROS level increased in Db/Db group (P<0.05). Compared with Db/Db group, ALP activity decreased, aortic hypertrophy decreased, vasodilation function improved, and ROS level of aorta decreased in MR409 group (P<0.05). Compared with WT group, there was significant VC in Db/Db group, which showed increased calcium salt deposition and increased Runx2 protein expression in aorta (P<0.05). Compared with Db/Db group, calcium salt deposition and Runx2 protein expression in aorta were decreased in MR409 group (P<0.05). Conclusion MR409 can significantly inhibit VC, reduce aortic hypertrophy and improve vascular endothelial function in diabetic mice, and its mechanism may be related to the inhibition of the increase of Runx2 expression induced by oxidative stress.

    Reference
    [1] 孙学娇, 刘乃丰.关注糖尿病与血管钙化的共同发病机制和临床意义.中国动脉硬化杂志, 0,8(2):169-174.
    [2] PROUDFOOT D, SHANAHAN C M.Biology of calcification in vascular cells:intimaversus media.Herz, 1,6(4):245-251.
    [3] 生杰, 赵久阳.慢性肾脏病患者的心血管钙化.中国血液净化, 2,1(1):49-50.
    [4] MOON A R, PARK Y, CHANG J H, et al.Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification:an observational study.Medicine (Baltimore), 9,8(10):e14489.
    [5] 王倩, 马涛, 程治源, 等.睾酮对维生素D3和尼古丁诱导的主动脉血管钙化的影响.中国动脉硬化杂志, 9,7(2):126-130.
    [6] JRG U, CUONG H V, BOGUSZ T, et al.Osteocalcin, osteopontin and RUNX2 expression in patients’ leucocytes with arteriosclerosis.Diseases, 1,9(1):19.
    [7] 韦珍妮.浅谈高磷血症致慢性肾脏病血管钙化的研究及治疗进展.临床检验杂志(电子版), 0,9(1):241-242.
    [8] SCHALLY A V, WANG H, HE J, et al.Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.Proc Natl Acad Sci USA, 8,5(47):12028-12033.
    [9] GESMUNDO I, MIRAGOLI M, CARULLO P, et al.Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.Proc Natl Acad Sci USA, 7,4(45):12033-12038.
    [10] ZHANG X, CUI T, HE J, et al.Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice.Proc Natl Acad Sci USA, 5,2(44):13651-13656.
    [11] BAGNO L, SUNCION V Y, SCHALLY A V, et al.Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy.J Am Heart Assoc, 5,4(4):e001464.
    [12] THOUNAOJAM M C, POWELL F L, PATEL S, et al.Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy.Proc Natl Acad Sci USA, 7,4(50):13248-13253.
    [13] SHEN J, ZHANG N, LIN Y N, et al.Regulation of vascular calcification by growth hormone-releasing hormone and its agonists.Circ Res, 8,2(10):1395-1408.
    [14] 陈澄, 覃春美, 欧三桃, 等.Ⅱ型糖尿病肾病大鼠肾动脉与肾内小动脉钙化及BMP2和Runx2的表达.西部医学, 7,9(2):154-158.
    [15] GAO J, ZHANG K, CHEN J, et al.Roles of aldosterone in vascular calcification:an update.Eur J Pharmacol, 6,6:186-193.
    [16] KAO H W, LIOU M, CHUNG H W, et al.Middle cerebral artery calcification:association with ischemic stroke.Medicine (Baltimore), 5,4(50):e2311.
    [17] 吴胜英, 董晓霞, 龚应霞, 等.靶向骨硬化蛋白治疗骨质疏松与血管钙化:一石二鸟或不可兼得.湖北医药学院学报, 7,6(2):187-190.
    [18] IZDEBSKI J, PINSKI J, SCHALLY A V, et al.Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.Proc Natl Acad Sci USA, 5,2(11):4872-4876.
    [19] KIARIS H, CHATZISTAMOU I, PAPAVASSILIOU A G, et al.Growth hormone-releasing hormone:not only a neurohormone.Trends Endocrinol Metab, 1,2(8):311-317.
    [20] CLAUDIA P, FABIO S, FRANCESCA T, et al.GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways.Endocrinology, 3,4(4):1624-1635.
    [21] ROMERO M J, LUCAS R, DOU H, et al.Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.Proc Natl Acad Sci USA, 6,3(7):1895-1900.
    [22] FRIDLYAND L E, TAMARINA N A, SCHALLY A V, et al.Growth hormone-releasing hormone in diabetes.Front Endocrinol (Lausanne), 6,7:129.
    [23] BYON C H, HEATH J M, CHEN Y, et al.Redox signaling in cardiovascular pathophysiology:a focus on hydrogen peroxide and vascular smooth muscle cells.Redox Biol, 6,9:244-253.
    [24] KOMORI T.Signaling networks in RUNX2-dependent bone development.J Cell Biochem, 1,2(3):750-755.
    [25] ARUMUGAM B, VISHAL M, SHREYA S, et al.Parathyroid hormone-stimulationof RUNX2 during osteoblast differentiation via the regulation of lnc-SUPT3H-1:16 (RUNX2-AS1:32) and miR-6797-5p.Biochimie, 9,8:43-52.
    [26] SPEER M Y, LI X, HIREMATH P G, et al.Runx2/Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis.J Cell Bichem, 0,0(4):935-947.
    [27] WATANABE S, FUJII H, KONO K, et al.Influence of oxidative stress on vascular calcification in the setting of coexisting chronic kidney disease and diabetes mellitus.Sci Rep, 0,0(1):20708.
    [28] GONG L, LIU Y, QIAN J, et al.Hydroxyapatite nanocrystals stimulate osteogenic differentiation in primary human aortic smooth muscle cells by activation of oxidative stress and the ERK pathway.Int J Clin Exp Pathol, 7,0(7):7726-7733.
    [29] TTH A, BALOGH E, JENEY V.Regulation of vascular calcification by reactive oxygen species.Antioxidants (Basel), 0,9(10):963.
    [30] LIBERMAN M, JOHNSON R C, HANDY D E, et al.Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification.Biochem Biophys Res Commun, 1,3(3):436-441.
    [31] CHAO C T, YEH H Y, TSAI Y T, et al.Natural and non-natural antioxidative compounds:potential candidates for treatment of vascular calcification.Cell Death Discov, 9,5(1):145.
    Cited by
Get Citation

XUE Ruize, CAI Ruiping, TANG Qi, LIU Yueyang, XU Qian, ZHOU Mingsheng. Growth hormone releasing hormone receptor agonist MR409 attenuates vascular calcification in diabetic Db/Db mice[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(8):661-667.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:November 12,2020
  • Revised:February 06,2021
  • Online: August 10,2021
Article QR Code